Literature DB >> 6970615

Reversal of the in vitro methotrexate suppression of cell-mediated immune response by folinic acid and thymidine plus hypoxanthine.

D Bogyo, E Mihich.   

Abstract

The development of a primary complement-independent cellular cytotoxic immune response in culture by C57BL/6J spleen cells stimulated with X-irradiated allogeneic P815 tumor cells was inhibited more than 50% in the presence of 1.5 X 10(-8) M methotrexate. This immunosuppression by methotrexate was time and dose dependent. Equimolar folinic acid administered at either -4, 0, +4, or +24 hr relative to 1.5 X 10(-8) M methotrexate reversed immunosuppression by more than 50%. Increased folinic acid concentration (5 to 10-fold) completely restored the immune response only if added 4 hr prior to methotrexate. Thymidine plus hypoxanthine (100 microM each) when present throughout the 4-day culture period gave total reversal of immunosuppression. The reversal was also obtained with hypoxanthine alone and was dose dependent. These results indicate that reversal of the methotrexate-induced impairment of cellular immune function depends on several parameters including the concentration of methotrexate and of the reversing agents as well as the time of exposure of relevant target cells to these agents.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6970615

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  2 in total

1.  Long-duration intracavitary infusion of methotrexate with systemic leucovorin protection in patients with malignant effusions.

Authors:  S B Howell; B B Chu; W E Wung; B M Metha; J Mendelsohn
Journal:  J Clin Invest       Date:  1981-04       Impact factor: 14.808

2.  Cytochalasin-B-induced immunosuppression of murine allogeneic anti-tumor response and the effect of recombinant human interleukin-2.

Authors:  D Bogyo; S R Fondy; L Finster; C Fondy; S Patil; T P Fondy
Journal:  Cancer Immunol Immunother       Date:  1991       Impact factor: 6.968

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.